BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
46.015 EUR
-0.37 (-0.79%)
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 54 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM is valued quite cheap, while showing a decent growth score. This is a good combination! Finally BRM also has an excellent dividend rating. These ratings could make BRM a good candidate for value and dividend investing.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
In the past year BRM had a positive cash flow from operations.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM has a Return On Assets of 6.23%. This is comparable to the rest of the industry: BRM outperforms 55.56% of its industry peers.
BRM has a better Return On Equity (32.55%) than 83.33% of its industry peers.
BRM's Return On Invested Capital of 16.42% is fine compared to the rest of the industry. BRM outperforms 79.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 13.79%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
With a Profit Margin value of 12.57%, BRM perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
With an excellent Operating Margin value of 33.51%, BRM belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
BRM's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 73.15%, BRM is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
Compared to 1 year ago, BRM has less shares outstanding
BRM has less shares outstanding than it did 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.23. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.23, BRM is in line with its industry, outperforming 42.59% of the companies in the same industry.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
BRM has a better Debt to FCF ratio (3.20) than 61.11% of its industry peers.
A Debt/Equity ratio of 2.41 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a Debt to Equity ratio of 2.41. This is amonst the worse of the industry: BRM underperforms 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
ROIC/WACC1.94
WACC8.45%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a Current ratio of 1.27. This is in the lower half of the industry: BRM underperforms 64.81% of its industry peers.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 460.68%, which is quite impressive.
Measured over the past years, BRM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
The Revenue has been growing slightly by 1.26% in the past year.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -4.97% on average per year.
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.26%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-4.97%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.26, which indicates a very decent valuation of BRM.
90.74% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.57. BRM is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 8.95, which indicates a very decent valuation of BRM.
Based on the Price/Forward Earnings ratio, BRM is valued cheaply inside the industry as 88.89% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BRM to the average of the S&P500 Index (24.04), we can say BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.95 |
4.2 Price Multiples
BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 90.74% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.22 | ||
| EV/EBITDA | 6.75 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y130.59%
EPS Next 3Y73.3%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 39.80%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.37, BRM pays a better dividend. On top of this BRM pays more dividend than 100.00% of the companies listed in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.8% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
FRA:BRM (12/23/2025, 7:00:00 PM)
46.015
-0.37 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap93.68B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target47.16 (2.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.8% |
Yearly Dividend2.05
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.69%
PT rev (3m)6.1%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)5.91%
EPS NY rev (1m)1.03%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)1.97%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.95 | ||
| P/S | 2.3 | ||
| P/FCF | 7.22 | ||
| P/OCF | 6.64 | ||
| P/B | 5.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.75 |
EPS(TTM)5.57
EY12.1%
EPS(NY)5.14
Fwd EY11.18%
FCF(TTM)6.38
FCFY13.86%
OCF(TTM)6.93
OCFY15.05%
SpS20.02
BVpS7.73
TBVpS-9.86
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.23 |
F-Score6
WACC8.45%
ROIC/WACC1.94
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.97%
EBIT Next 3Y49.92%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 478.44% in the next year.